| Issuer | % of Class | Filed | ||||
|---|---|---|---|---|---|---|
| Schedule 13D · 1 security · may seek to influence control | ||||||
|
Vigil Neuroscience, Inc.
13D/A
VIGL · 92673K108
|
0% |
5/27/2025
Event 5/22/2025
|
||||
| Northpond Ventures, LP | 0% | |||||
| Northpond Ventures GP, LLC | 0% | |||||
| Northpond Ventures II, LP | 0% | |||||
| Northpond Ventures II GP, LLC | 0% | |||||
| Michael P. Rubin | 0% | |||||
| Schedule 13G · 2 securities · passive | ||||||
|
Mereo BioPharma Group plc
13G/A
MREO · 589492107
|
0% |
2/17/2026
Event 12/31/2025
|
||||
| Northpond Ventures, LP | 0% | |||||
| Northpond Ventures GP, LLC | 0% | |||||
| Northpond Ventures II, LP | 0% | |||||
| Northpond Ventures II GP, LLC | 0% | |||||
| NPV Listed, LLC | 0% | |||||
| Northpond Ventures, LLC | 0% | |||||
| Michael P. Rubin | 0% | |||||
|
Candel Therapeutics, Inc.
13G/A
CADL · 137404109
|
0% |
2/14/2025
Event 12/31/2024
|
||||
| Northpond Ventures, LP | 0% | |||||
| Northpond Ventures GP, LLC | 0% | |||||
| Northpond Ventures II, LP | 0% | |||||
| Northpond Ventures II GP, LLC | 0% | |||||
| Michael P. Rubin | 0% | |||||
Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.